ZYNE - Zynerba Pharmaceuticals, Inc.
| Previous Close | 11.30 |
| Open | 11.25 |
| Bid | 10.86 x 1000 |
| Ask | 10.91 x 800 |
| Day's Range | 10.70 - 11.35 |
| 52 Week Range | 5.42 - 20.73 |
| Volume | 179,104 |
| Avg. Volume | 230,806 |
| Market Cap | 145.552M |
| Beta | 4.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.79 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.50 |
- GlobeNewswire•18 days ago
Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday June 7, 2018 at 10:30 AM EDT at the Grand Hyatt hotel in New York, NY. Zynerba Pharmaceuticals (ZYNE) is a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders with high unmet medical needs.
- Oilprice.com•22 days ago
The Tech Revolutionizing The Billion Dollar Marijuana Business
Reefer madness is reaching a full-blown frenzy, with total legal worldwide marijuana sales expected to surpass $63 billion in less than ten years. And now the tech behind bitcoin is poised to take the cannabis boom to the next level
- Investopedia•last month
Pot Stock Winners of the Week
Here are the week's four biggest marijuana stock winners.
- Simply Wall St.•last month
Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed Recently
Understanding how Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...
- Associated Press•last month
Zynerba: 1Q Earnings Snapshot
The Devon, Pennsylvania-based company said it had a loss of 91 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa., May 08, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure. LOS ANGELES, April 25, 2018-- Zynerba Pharmaceuticals, ...
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced an oral presentation to be given at the16th NFXF (National Fragile X Foundation) International Fragile X Conference. The oral presentation will describe data from the FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study that highlight the short- and long-term positive impact of ZYN002 on children and adolescents with Fragile X syndrome (FXS). Zynerba is committed to supporting the needs of patients, their families and health care practitioners, and to developing this novel therapy to treat the behavioral symptoms associated with Fragile X syndrome as expeditiously as possible,” said Dr. Liza Squires, Zynerba’s Chief Medical Officer.
- Simply Wall St.•2 months ago
What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?
The most recent earnings announcement Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) released in December 2017 confirmed that losses became smaller relative to the prrior year’s level as a result of recent tailwindsRead More...
- Investor's Business Daily•2 months ago
Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
DEVON, Pa., April 16, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
DEVON, Pa., April 10, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- Simply Wall St.•2 months ago
Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
- GlobeNewswire•3 months ago
Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
DEVON, Pa., March 26, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- GlobeNewswire•3 months ago
Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
DEVON, Pa., March 22, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- Simply Wall St.•3 months ago
Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The US$136.43M market-cap company announced a latest loss of -US$32.01M on 31 December 2017 forRead More...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / U.S. markets were mixed Mondays as concerns over a potential trade war overshadowed Friday’s jobs data. The Dow Jones Industrial Average declined 0.62 percent ...
- Associated Press•3 months ago
Zynerba reports 4Q loss
The Devon, Pennsylvania-based company said it had a loss of 60 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- ACCESSWIRE•3 months ago
Wired News – Zynerba Pharma Held Positive Discussion Meeting with FDA for its ZYN002 Development Strategy
Stock Monitor: Horizon Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 07, 2018 / Active-Investors.com has just released a free research report on Zynerba Pharma, Inc. (NASDAQ: ZYNE ). If ...
- American City Business Journals•3 months ago
Main Line pharma company plans key study of Fragile X syndrome therapy
Zynerba Pharmaceuticals said Monday it plans — with the Food and Drug Administration's approval — to initiate a single pivotal study later this year to support a new drug application for its experimental cannabis-based treatment for Fragile X Syndrome. Fragile X is a rare genetic developmental disability that is a leading known cause of both inherited intellectual disability and autism spectrum disorder. Zynerba, of Devon, Pa, said its game plan for its new drug candidate, ZYN002, came following a meeting with the Food and Drug Administration.
- 24/7 Wall St.•5 months ago
Can Zynerba Pharma Shares Really Still Double in These High Times?
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
